Abstract
Objective: To evaluate the profile of intravenous human immunoglobulin use in adult patients hospitalized at a hIgh-complexity university hospital. Methods: An observational, descriptive, and retrospective study was conducted with 53 adult patients who had a request for intravenous human immunoglobulin during the evaluated period. Sociodemographic, clinical, care-related, and funding variables were analyzed, including ICD-10 diagnosis, medical specialty, length of hospital stay, time to medication access, and funding source. Data were analyzed using descriptive statistics. Results: A similar distribution between sexes was observed, with a slight predominance of females (50.1%), and a high frequency among young adults, particularly those aged 15 to 22 years (24.5%). Requests were mainly related to nervous system diseases and blood and hematopoietic disorders, accounting for more than 90% of indications, predominantly managed by Neurology (58.5%) and Hematology (22.6%). Most patients had associated comorbidities (58.5%), and 48.9% accessed the medication within one day after prescription. Funding was predominantly provided by the Specialized Component of Pharmaceutical Care. Conclusion: Intravenous human immunoglobulin use was largely consistent with national guidelines, highlighting the importance of monitoring and rational management of this high-cost therapy in public hospitals.
References
ALMAGRO MJ, et al. Impact of hospital pharmacy interventions on the use of hIgIV-cost medications: a multicenter study. International Journal of Clinical Pharmacy, 2018; 40(5): 1153–1162.
BALLOW M, SHEHATA N. Intravenous immune globulin: clinical uses. UpToDate, 2024.
BENNETT CL, et al. The role of pharmacy and therapeutic committees in high-cost drug decision-making: experiences from hospital systems. Journal of Managed Care & Specialty Pharmacy, 2019; 25(7): 790–798
BRASIL. Protocolo Clínico e Diretrizes Terapêuticas: Imunoglobulina Humana Endovenosa. Ministério da Saúde, 2017. Disponível em: https://www.gov.br/saude. Acessado em: 15 de novembro de 2025.
DALAKAS MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA, 2004; 291(19): 2367-2375.
EMPRESA BRASILEIRA DE SERVIÇOS HOSPITALARES (EBSERH). Hospital Universitário da Universidade Federal do Maranhão (HU-UFMA): acesso à informação institucional. s.d. Disponível em: https://www.gov.br/ebserh/pt-br/hospitais-universitarios/regiao-nordeste/hu-ufma/acesso-a-informacao/institucional. Acesso em: 17 de janeiro de 2026.
EUROPEAN MEDICINES AGENCY (EMA). Human normal immunoglobulins – supply shortage. 2024. Disponível em: https://www.ema.europa.eu/en/medicines/human/shortages/human-normal-immunoglobulins. Acessado em: 10 de janeiro de 2026.
FERNANDES BS, TEIXEIRA CA. Perfil de uso de imunoglobulina humana intravenosa em um hospital universitário no Rio de Janeiro. Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, 2022; 13(2): 0748.
GOUDOURIS ES, et al. Uso racional da imunoglobulina humana no Brasil. Revista Brasileira de Alergia e Imunopatologia, 2017; 40(1): 1-8.
INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA (IBGE). Pesquisa Nacional por Amostra de Domicílios Contínua – PNAD Contínua 2023: conceitos e definições de atividade econômica. Rio de Janeiro: IBGE, 2023. Disponível em: https://www.ibge.gov.br. Acessado em: 06 de janeiro de 2026.
INFARMED. Normas orientadoras para a utilização de imunoglobulina humana. 2020. Disponível em: https://www.infarmed.pt. Acessado em: 11 de dezembro de 2026.
JUSTIZ-VAILLANT A, et al. Efficacy of intravenous immunoglobulins and other immunotherapeutic strategies in autoimmune and neuroimmune conditions. Public Health Immunology, 2025; 5(2): 18.
LOPES GR, et al. Hospital pharmacists' contribution to multidisciplinary committees and health technology management: a systematic review. Research in Social and Administrative Pharmacy, 2021; 17(6): 1075–1084.
ORANGE JS, et al. Use of intravenous immunoglobulin in human disease: a review of evidence. Journal of Allergy and Clinical Immunology, 2020; 117(4 Suppl): S525-S553.
ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). WHO model list of essential medicines: immunoglobulins. 2021. Disponível em: https://www.who.int. Acessado em: 17 de novembro de 2026.
PEREZ EE, et al. Adverse effects of intravenous immunoglobulin. UpToDate, 2024.
MOREIRA TM, et al. Clinical pharmacy services and cost containment in hIgh-complexity hospitals: an evaluative study. Hospital Pharmacy, 2022; 57(4): 217–224.
SEIDMAN MA, JONES KD. Intravenous immunoglobulin therapy in autoimmune and inflammatory diseases. Clinical Medicine, 2021; 21(6): e595-e600.
SHI J, et al. The role of hospital pharmacists in supporting the appropriate use of hIgh-cost medications. BMC Health Services Research, 2025; 25:12026.
SPACIL CR, et al. Padrões de prescrição e utilização de imunoglobulina humana endovenosa em ambiente hospitalar: análise de indicações fora dos protocolos clínicos. Arquivos de Asma, Alergia e Imunologia, 2017; 1(3): 293-298.
SUPPLY PROJECT – EU4Health. Final recommendations for immunoglobulin prioritization and appropriate use. 2024. Disponível em: https://supply-project.eu/wp-content/uploads/2024/02/D6.2-Recommendation-report-enabling-informed-and-appropriate-prioritisation-on-national-level.pdf. Acessado em: 05 de dezembro de 2026.
TAHA SA, et al. Intravenous immunoglobulin therapy: utilization patterns, clinical indications and safety
profile in a tertiary hospital setting. Frontiers in Immunology, 2024; 15: 1481079.
